Stoke Therapeutics (STOK) said Wednesday that the first patient has received a dose in an early-stage trial of STK-002 for the treatment of Autosomal Dominant Optic Atrophy, an inherited vision loss condition.

The open-label study's primary objective will be to evaluate the safety and tolerability of the investigational medicine in patients between the ages of 6 and 55, the company said.

Researchers plan to monitor changes in visual function, eye structure, and quality of life as secondary goals of the clinical program, the company added.

Stoke Therapeutics said the trial is currently enrolling participants with a confirmed genetic mutation linked to the condition in Germany and the UK, with additional European sites expected to activate in the coming months.

The company also said the dose escalation for the initial four groups is expected to continue through this year and into early next year.